化滞柔肝颗粒治疗非酒精性脂肪性肝病疗效观察

Observation of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver disease

目的观察化滞柔肝颗粒治疗非酒精性脂肪性肝病(NAFLD)的临床疗效。方法将60例NAFLD患者随机分为2组,对照组30例口服水飞蓟宾葡甲胺片,治疗组30例口服化滞柔肝颗粒,2组均治疗12周。比较2组患者治疗前后症状积分、血清肝酶、血脂、体质量指数和肝脏B超分度情况。结果治疗组总有效率为87%,对照组为67%,2组比较差异有统计学意义(P<0.05);治疗组症状积分、体质量指数、血脂和肝脏B超分度改善情况均明显优于对照组(P均<0.05);2组治疗后肝功能均有改善,但组间比较差异无统计学意义(P>0.05)。结论化滞柔肝颗粒治疗NAFLD疗效较好,其疗效机制有待进一步探讨。

Objective It is to observe the clinical curative effect of Huazhi Rougan granule （HZRGG） in the treatment of nonalcoholic fatty liver disease （NAFLD）. Methods 60 patients with NAFLD were randomly divide into two groups. 30 cases in control group were treated with oral-taken milk thistle meglumine while 30 cases in treatment group were treated with HZRGG, and all patients were treated for 12 weeks. The symptom score, serum liver enzyme, blood lipid, body mass index and liver ultrasound division of the two groups before and after treatment were compared. Results The total effective rate of treatment group was 87% while the control group was 67% , there was significant differenee （P 〈 0.05 ）. The symptoms score, body mass index, blood lipid and liver ultrasound division of the treatment group were significantly better than that of control group （ P 〈 0. 05 ）. The liver functions of each group were improved after treatment ; there was no significant difference between the two groups （P 〉 0.05）. Conclusion HZRGG has an effective curative effect on the treatment of NAFLD, thought its mechanism is yet to be further studied.